These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10714565)

  • 1. Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy.
    Precious HM; Günthard HF; Wong JK; D'Aquila RT; Johnson VA; Kuritzkes DR; Richman DD; Leigh Brown AJ
    AIDS; 2000 Jan; 14(1):31-6. PubMed ID: 10714565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy.
    Brown AJ; Günthard HF; Wong JK; D'Aquila RT; Johnson VA; Kuritzkes DR; Richman DD
    J Infect Dis; 1999 Oct; 180(4):1043-9. PubMed ID: 10479129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
    Conway B; Wainberg MA; Hall D; Harris M; Reiss P; Cooper D; Vella S; Curry R; Robinson P; Lange JM; Montaner JS
    AIDS; 2001 Jul; 15(10):1269-74. PubMed ID: 11426071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
    Flandre P; Descamps D; Joly V; Meiffrédy V; Tamalet C; Izopet J; Aboulker JP; Brun-Vézinet F
    Antivir Ther; 2003 Feb; 8(1):65-72. PubMed ID: 12713066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.
    Miller V; Ait-Khaled M; Stone C; Griffin P; Mesogiti D; Cutrell A; Harrigan R; Staszewski S; Katlama C; Pearce G; Tisdale M
    AIDS; 2000 Jan; 14(2):163-71. PubMed ID: 10708287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial).
    Antivir Ther; 2002 Mar; 7(1):11-20. PubMed ID: 12008783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
    Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
    JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group.
    Pellegrin I; Izopet J; Reynes J; Denayrolles M; Montes B; Pellegrin JL; Massip P; Puel J; Fleury H; Segondy M
    AIDS; 1999 Sep; 13(13):1705-9. PubMed ID: 10509572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
    Ait-Khaled M; Rakik A; Griffin P; Cutrell A; Fischl MA; Clumeck N; Greenberg SB; Rubio R; Peters BS; Pulido F; Gould J; Pearce G; Spreen W; Tisdale M; Lafon S;
    Antivir Ther; 2002 Mar; 7(1):43-51. PubMed ID: 12008787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
    Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.
    Hanna GJ; Johnson VA; Kuritzkes DR; Richman DD; Brown AJ; Savara AV; Hazelwood JD; D'Aquila RT
    J Infect Dis; 2000 Mar; 181(3):904-11. PubMed ID: 10720511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
    Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir.
    Pérez-Elías MJ; Moreno S; Gutiérrez C; López D; Abraira V; Moreno A; Dronda F; Casado JL; Antela A; Rodríguez MA
    AIDS; 2005 Apr; 19(7):695-8. PubMed ID: 15821395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of zidovudine-resistance mutations in HIV-1 isolates from patients removed from zidovudine therapy for at least 3 years and switched to a stavudine-containing regimen.
    Pellegrin I; Garrigue I; Caumont A; Pellegrin JL; Merel P; Schrive MH; Bonot P; Fleury H
    AIDS; 2001 May; 15(8):1071-3. PubMed ID: 11399996
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
    Caride E; Brindeiro R; Hertogs K; Larder B; Dehertogh P; Machado E; de Sá CA; Eyer-Silva WA; Sion FS; Passioni LF; Menezes JA; Calazans AR; Tanuri A
    Virology; 2000 Sep; 275(1):107-15. PubMed ID: 11017792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
    Veldkamp AI; Weverling GJ; Lange JM; Montaner JS; Reiss P; Cooper DA; Vella S; Hall D; Beijnen JH; Hoetelmans RM
    AIDS; 2001 Jun; 15(9):1089-95. PubMed ID: 11416710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine.
    Marcelin AG; Flandre P; Furco A; Wirden M; Molina JM; Calvez V;
    Antivir Ther; 2006; 11(6):693-9. PubMed ID: 17310813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs.
    de Jong JJ; Goudsmit J; Lukashov VV; Hillebrand ME; Baan E; Huismans R; Danner SA; ten Veen JH; de Wolf F; Jurriaans S
    AIDS; 1999 Jan; 13(1):75-80. PubMed ID: 10207547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients.
    Shafer RW; Winters MA; Palmer S; Merigan TC
    Ann Intern Med; 1998 Jun; 128(11):906-11. PubMed ID: 9634429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.